🔎 Trials Near Me

Utama › Limfoma Burkitt › North Dakota

Kajian klinikal Limfoma Burkitt di North Dakota

5 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi di North Dakota.

Bandar di North Dakota

Teks kajian rasmi (Bahasa Inggeris)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sanford Broadway Medical Center, Fargo
Mengambil pesertaFasa 2
366 Days – 46 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sanford Broadway Medical Center, Fargo
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sanford Broadway Medical Center, Fargo
Mengambil pesertaFasa 2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Sanford Broadway Medical Center, Fargo
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.